QID 317159

Date Published: 2022-06-29

QID 317159: Cisco Internetwork Operating System (IOS) XE Software Border Gateway Protocol Resource Public Key Infrastructure Denial of Service (DoS) Vulnerability (cisco-sa-iosxe-rpki-dos-2EgCNeKE)

A vulnerability in the implementation of the Resource Public Key Infrastructure (RPKI) feature of Cisco IOS XE Software
could allow an unauthenticated, remote attacker to cause the Border Gateway Protocol (BGP)
process to crash, resulting in a denial of service (DoS) condition.

Affected Products
Cisco devices if they were running a vulnerable release of IOS XE Software and had the RPKI feature configured and in use.

QID Detection Logic (Authenticated):
The check matches Cisco IOS XE version retrieved via Unix Auth using "show version" command.
QID Detection Logic (Unauthenticated):
The check matches Cisco IOS XE version retrieved via SNMP or TCP/IP Fingerprint or NTP or Telnet.

A successful exploit could allow the attacker to cause a DoS condition because the BGP process could constantly restart and BGP routing could become unstable.

  • CVSS V3 rated as High - 6.8 severity.
  • CVSS V2 rated as High - 7.1 severity.
    • Solution

    Customers are advised to refer to cisco-sa-iosxe-rpki-dos-2EgCNeKE for more information.

    Vendor References

    CVEs related to QID 317159

    CVE-2022-20694 |
    Software Advisories
    Advisory ID Software Component Link
    cisco-sa-iosxe-rpki-dos-2EgCNeKE URL Logo tools.cisco.com/security/center/content/CiscoSecurityAdvisory/cisco-sa-iosxe-rpki-dos-2EgCNeKE
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].